Company / Capital Expenditures
Cardiff Oncology, Inc. Capital Expenditures History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$44.0K
FY2025
5-year range
$44.0K / $1.0M
FY2021-FY2025
Trend
-92.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Capital Expenditures has fluctuated over the past 10 years, ranging from $44,000 in FY2025 to $1M in FY2023.
Based on SEC 10-K filings.
$44,000 in FY2025 with a 5-year CAGR of -26.9%.
Declined from $1M to $44,000 over the past 2 years.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -40.1%
- 5-Year CAGR
- -26.9%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -26.9%, indicating a declining trend.
- In FY2025, capital expenditures decreased 92.4% year-over-year.
- Peak capital expenditures was recorded in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -6.67 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $44.0K | -92.4% |
| FY2024 | $582.0K | -42.1% |
| FY2023 | $1.0M | +390.7% |
| FY2022 | $205.0K | -2.8% |
| FY2021 | $211.0K | +0.0% |
| FY2020 | $211.0K | +212.0% |
| FY2019 | $67.6K | -33.1% |
| FY2018 | $101.1K | -87.7% |
| FY2017 | $823.5K | +126.7% |
| FY2016 | $363.3K | -83.8% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026